Abstract
Atrial fibrillation (AF) is the most common form of cardiac arrhythmia and is associated with an increased risk of cardiovascular morbidity and mortality, especially due to ischemic stroke. The occurrence of AF leads to atrial electrical and structural remodeling. The renin-angiotensin system appears to play a role in the development of atrial arrhythmias by its involvement in both of these processes. Large-scale hypertension trials and heart failure trials have indicated the potential value of angiotensin II receptor blockers in the treatment of AF.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 783-791 |
| Number of pages | 9 |
| Journal | Vascular Health and Risk Management |
| Volume | 5 |
| State | Published - Dec 1 2009 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
All Science Journal Classification (ASJC) codes
- Endocrinology, Diabetes and Metabolism
- Hematology
- Public Health, Environmental and Occupational Health
- Cardiology and Cardiovascular Medicine
- Pharmacology (medical)
Fingerprint
Dive into the research topics of 'Angiotensin II receptor blockers in the prevention of complications from atrial fibrillation'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver